Ifeanyichukwu Ifechidere: TTP and ADAMTS-13 – The Enzyme Deficiency That Can Kill in 24 Hours
Ifeanyichukwu Ifechidere, Specialist Biomedical Scientist at Sheffield Teaching Hospitals NHS Foundation Trust, shared a post on LinkedIn:
“TTP and ADAMTS-13: The Enzyme Deficiency That Can Kill in 24 Hours
If you take one haematological emergency seriously enough to recognise at 2am, make it this one.
Thrombotic Thrombocytopenic Purpura (TTP) is rare – but untreated, it’s fatal in over 90% of cases. Treated promptly, survival flips to over 80%.
That gap is entirely about recognition speed.
What’s actually happening
Normally, ultra-large von Willebrand factor (ULVWF) multimers released from endothelial cells are cleaved down to smaller, less ‘sticky’ forms by an enzyme called ADAMTS-13.
In TTP, ADAMTS-13 activity is severely deficient (typically less than 10%) – either through:
- Autoantibody inhibition (acquired/immune TTP – the majority of cases)
- Inherited mutation (congenital TTP / Upshaw-Schülman syndrome – rare)
Without ADAMTS-13 doing its job, ULVWF multimers stay huge and hyperactive.
They spontaneously bind platelets, triggering widespread microthrombi in small vessels – consuming platelets and shearing red cells as they pass through.
The clinical picture (classic pentad – rarely all present)
- Microangiopathic haemolytic anaemia (schistocytes on film )
- Thrombocytopenia
- Neurological symptoms
- Renal impairment
- Fever
In practice, you’ll usually see the first two plus organ involvement – waiting for all five delays diagnosis and costs lives.
The lab clues that should raise suspicion
- Low platelets plus anaemia plus schistocytes on blood film
- Normal PT/APTT/fibrinogen – this is what separates TTP from DIC
- Elevated LDH and bilirubin (haemolysis markers)
- Negative direct Coombs test (rules out immune haemolytic anaemia)
Confirmatory test: ADAMTS-13 activity assay — severe deficiency (less than 10%) confirms diagnosis. Anti-ADAMTS-13 antibodies confirm the acquired form.
Why this matters so much in the lab: TTP is a clinical diagnosis first.
Waiting for ADAMTS-13 results (which can take days) before starting treatment is a fatal delay.
The PLASMIC score is often used at the bedside to estimate pre-test probability while results are pending.
Management essentials
- Plasma exchange (PEX) – the cornerstone, removes autoantibodies and ULVWF, replenishes ADAMTS-13
- Corticosteroids – immunosuppression for the autoimmune process
- Caplacizumab – anti-VWF nanobody, blocks platelet binding while PEX takes effect
- Platelet transfusion is generally AVOIDED unless life-threatening bleeding — it can fuel further microthrombosis
The lab’s role: A same-day film review flagging schistocytes, alongside a normal coagulation screen, can be the trigger that gets PEX started before ADAMTS-13 results are back.
That turnaround is where biomedical scientists directly save lives.”

Other posts featuring Ifeanyichukwu Ifechidere on Hemostasis Today.
-
Nov 10, 2026, 16:28Can the VWF to ADAMTS-13 Ratio Predict Mortality in Sepsis-Induced Coagulopathy? – RPTH Journal
-
Nov 10, 2026, 16:28Ruth Willems: PhD Defence at Maastricht University on Thrombosis and Bleeding in HPB Disease
-
Nov 10, 2026, 16:09Edward Lee Carter: Factor XIa Inhibition Enters Clinical Practice
-
Nov 10, 2026, 16:08Edward C.C. Wong: Deriving Ferritin Cutoffs for Iron Deficiency Using RBC Parameters
-
Nov 10, 2026, 16:07Milad Abdalla: Decoding Hemoglobin Electrophoresis – A Practical Diagnostic Reference
-
Nov 10, 2026, 15:13Wolfgang Miesbach: Nonviral Gene Therapy for Haemophilia A Using Lipid Nanoparticles
-
Nov 10, 2026, 15:06Dahra Teles: First Speaking Experience at HEMO 2026 on First-Line Multiple Myeloma Treatment
-
Nov 10, 2026, 14:55Yazan Abou-Ismail: First FDA-Approved Factor XIa Inhibitor for Stroke Prevention
-
Nov 10, 2026, 14:49Ifeanyichukwu Ifechidere: The Role of Coagulation in Anaesthesia and Surgery